Peter Ackerman

1.3k citations

30 papers · 523 indexed · h-index 11

Impact in

Virology top 5%
- HIV Research and Treatment
Hepatology top 5%
- Hepatitis C virus research

Papers in ⓘ

Virology 16
- HIV Research and Treatment 16
Infectious Diseases 24
- HIV/AIDS drug development and treatment 22
- HIV/AIDS Research and Interventions 13

Co-authors: Cyril Llamoso (13 shared papers)Mindy Magee (9 shared papers)Max Lataillade (8 shared papers)Stephanie Noviello (4 shared papers)Anne F. Luetkemeyer (3 shared papers)Margaret Gartland (4 shared papers)Lan Kluwe (1 shared paper)Arie Perry (1 shared paper)
Journals: Open Forum Infectious Diseases (5 papers)Journal of Antimicrobial Chemotherapy (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)Clinical Infectious Diseases (1 paper)Gastroenterology (1 paper)
Partner nations: United States United Kingdom France

In The Last Decade

Peter Ackerman

29 papers receiving 514 citations

Peers

Countries citing papers authored by Peter Ackerman

Since Specialization

Citations

This map shows the geographic impact of Peter Ackerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ackerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ackerman more than expected).

Fields of papers citing papers by Peter Ackerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ackerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ackerman. The network helps show where Peter Ackerman may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Ackerman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Ackerman Line = papers co-authored together Peter Ackerman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues Cancer Research ·Shyra J. Miller, Fatima Rangwala, Jon Williams, Peter Ackerman, Sue Kong, Anil G. Jegga, Sérgio Kaiser, Bruce J. Aronow, Silke Frahm, Lan Kluwe, Victor Mautner, Meena Upadhyaya, David Muir, Margaret R. Wallace, Jussara Hagen, Dawn E. Quelle, Mark A. Watson, Arie Perry, David H. Gutmann, Nancy Ratner	2006	158
2	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection New England Journal of Medicine ·Michael D. Miller, Judith A. Aberg, Gilles Pialoux, Pedro Cahn, Melanie Thompson, Jean‐Michel Molina, Beatriz Grinsztejn, Ricardo Sobhie Diaz, Antonella Castagna, Princy Kumar, Gulam Latiff, Edwin DeJesus, Mark Gummel, Margaret Gartland, Amy Pierce, Peter Ackerman, Cyril Llamoso, Max Lataillade	2020	102
3	Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B Hepatology ·Maureen M. Jonas, Mei‐Hwei Chang, Étienne Sokal, Kathleen B. Schwarz, Déirdre Kelly, Kyung Mo Kim, Simon C. Ling, Philip Rosenthal, Dumitru Orăşeanu, Laurie Reynolds, Alexandra Thiry, Peter Ackerman	2015	51
4	12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens Clinical Infectious Diseases ·Anne F. Luetkemeyer, Cheryl McDonald, Moti Ramgopal, Stephanie Noviello, Rafia Bhore, Peter Ackerman	2016	45
5	LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study Journal of Hepatology ·D. Wyles, P. Ruane, Mark Sulkowski, Doug Dieterich, Anne F. Luetkemeyer, Tim Morgan, K.E. Sherman, Z. Liu, Stephanie Noviello, Peter Ackerman	2015	19
6	Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis Clinical and Translational Science ·Chakradhar V. Lagishetty, Katy Moore, Peter Ackerman, Cyril Llamoso, Mindy Magee	2020	17
7	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 AIDS ·Peter Ackerman, Melanie Thompson, Jean‐Michel Molina, Judith A. Aberg, Isabel Cassetti, Michael D. Miller, Antonella Castagna, Marcelo Martins, Moti Ramgopal, Eduardo Sprinz, Sandra Treviño‐Pérez, Adrian Streinu‐Cercel, Gulam Latiff, Gilles Pialoux, Princy Kumar, Marcia Wang, Shiven Chabria, Amy Pierce, Cyril Llamoso, Max Lataillade	2021	13
8	Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants British Journal of Clinical Pharmacology ·Katy Moore, Mindy Magee, Heather Sevinsky, Ming Chang, Susan Lubin, Elsa Myers, Peter Ackerman, Cyril Llamoso	2019	11
9	Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay Journal of Antimicrobial Chemotherapy ·Margaret Gartland, Nannan Zhou, Eugene L. Stewart, Amy Pierce, Andrew Clark, Peter Ackerman, Cyril Llamoso, Max Lataillade, Mark Krystal	2020	11
10	2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients Open Forum Infectious Diseases ·Katy Moore, A Savannah Mageau, Mindy Magee, Peter D. Gorycki, Peter Ackerman, Cyril Llamoso	2019	11
11	Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison Clinical Therapeutics ·Elyse Swallow, Jinlin Song, Yong Yuan, Anupama Kalsekar, Caroline Kelley, Miranda Peeples, Fan Mu, Peter Ackerman, James Signorovitch	2016	10
12	Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1 Antimicrobial Agents and Chemotherapy ·Margaret Gartland, Pedro Cahn, Edwin DeJesus, Ricardo Sobhie Diaz, Robert Grossberg, Michael D. Miller, Princy Kumar, Jean‐Michel Molina, Fernando Mendo Urbina, Marcia Wang, Fangfang Du, Shiven Chabria, Andrew Clark, Louise Garside, Mark Krystal, Frank Mannino, Amy Pierce, Peter Ackerman, Max Lataillade	2022	10
13	Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database Journal of Antimicrobial Chemotherapy ·Margaret Gartland, Éric Arnoult, Brian Foley, Max Lataillade, Peter Ackerman, Cyril Llamoso, Mark Krystal	2021	9
14	Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants Antimicrobial Agents and Chemotherapy ·Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda, Susan Lubin, Cyril Llamoso, Peter Ackerman	2022	8
15	Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment Open Forum Infectious Diseases ·Heather Sevinsky, Mindy Magee, Peter Ackerman, Robert Adamczyk, Jennifer Karkas, Susan Lubin, Palanikumar Ravindran, Cyril Llamoso, Timothy Eley, Katy Moore	2017	8
16	Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir The Journal of Clinical Pharmacology ·Mindy Magee, Jill Slater, Frank Mannino, Peter Ackerman, Cyril Llamoso, Katy Moore	2020	7
17	Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island. PubMed ·Francine Touzard Romo, Fizza S. Gillani, Peter Ackerman, Aadia Rana, Erna Milunka Kojic, Curt G. Beckwith	2014	7
18	Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects Xenobiotica ·Peter D. Gorycki, Mindy Magee, Peter Ackerman, Xiu‐Sheng Miao, Katy Moore	2022	5
19	Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co‐administration HIV Medicine ·Nneka Nwokolo, Elana Post, A. Savannah Mageau, Rimi Shah, Mindy Magee, Frank Mannino, Peter Ackerman, Andrew Clark, Katy Moore	2022	4
20	Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants SHILAP Revista de lepidopterología ·Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore	2022	3

About Peter Ackerman

Peter Ackerman is a scholar working on Virology, Infectious Diseases, Hepatology, Emergency Medicine and Pharmacology, having authored 30 papers that have together received 523 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (16 papers), HIV/AIDS Research and Interventions (13 papers), Hepatitis C virus research (9 papers), Pneumocystis jirovecii pneumonia detection and treatment (4 papers), HIV-related health complications and treatments (2 papers), Hepatitis B Virus Studies (2 papers) and Historical and Contemporary Political Dynamics (1 paper). The work is most often cited by research in Virology (176 citations), Hepatology (142 citations), Infectious Diseases (232 citations), Neurology (125 citations) and Epidemiology (165 citations). Peter Ackerman has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Cyril Llamoso, Mindy Magee, Max Lataillade, Stephanie Noviello, Anne F. Luetkemeyer, Margaret Gartland, Lan Kluwe, Arie Perry, Rafia Bhore and Moti Ramgopal. Their work appears in journals such as Open Forum Infectious Diseases, Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact